

REMARKS

At page 2 of the present Action, the Applicant's cooperation is requested in correcting any errors of which Applicant may become aware in the specification. Applicant's amendment to the specification is indicated above.

At page 3 of the present Action, the Examiner rejects claims 6-7 and 13 under 35 U.S.C. 101. Applicant respectfully notes that, with the present Amendment, Applicant cancels these claims. Applicant respectfully requests withdrawal of the rejection therefore. Applicant notes that cancelation of these claims is intended without prejudice.

At page 4 of the present Action, the Examiner rejects claims 6-7 and 13 under 35 U.S.C. 112. Applicant respectfully notes that, with the present Amendment, Applicant cancels these claims. Applicant respectfully requests withdrawal of the rejection therefore. Applicant notes that cancelation of these claims is intended without prejudice.

At pages 4-5 of the present Action, the Examiner rejects claims 1-4, 20 and 26 as indefinite under 35 U.S.C. 112, second paragraph, stating that the metes and bounds of the phrases "derivative", "analog", "pro-drug" and "N-oxide" cannot be ascertained, and that it is not clear if a derivative of formula (I) is a pro-drug or another form of the compounds of formula (I). In response, Applicant respectfully submits that the phrases "derivative", "analog", "N-oxide" and "pro-drug" no longer occur in these claims, and requests that the Examiner withdraw the rejection based on these terms therefore. The deletion of these terms is intended without prejudice.

Also, the Examiner states that subscript "n" in formula (1) has not been defined and that claim 1 is therefore indefinite. In response, Applicant respectfully submits that "n" is defined in the present claims, and requests withdrawal of this rejection.

Also, the Examiner states that in claim 1 and 20, the phrases "may be same or different" and "preparing a" have been repeated more than once. In response, Applicant respectfully submits the repeated phrases have been removed from these claims, and requests withdrawal of this rejection.

Also, the Examiner states that claim 20 is outside the scope of the elected invention because substituent "A" was limited in the restriction requirement in the previous Office Action to only carbon, and because "A" in claim 20 could be interpreted more broadly than the restricted invention. In response, Applicant respectfully submits that claim 20 is amended to read "wherein A is carbon", and requests that the Examiner withdraw this rejection.

Also, the Examiner indicates that the claim 20 phrase "preferably chloro, bromo or iodo" is indefinite. In response, Applicant notes that this phrase has been removed from claim 20, and requests that the Examiner withdraw the rejection therefore. The removal of these terms is intended without prejudice.

U.S. Patent Appln. No. 10/536,618
Response to Office Action dated April 26, 2010
Filed July 26, 2010

Atty. Docket No. SUB 0006 US

Also, the Examiner states the limitation “prodrug” in claim 26 line 5 lacks antecedent basis. In response, Applicant notes that the term “prodrug” no longer occurs in claim 26, and submits that this rejection is overcome therefore.

At page 6 of the present Action, the Examiner rejects claim 15 under 35 U.S.C. 112, stating the plethora of intended uses renders the intended amount ambiguous. The Examiner recommends deleting the uses, stating that only one use is needed to support the claim under US practice. In response, Applicant introduces new claims 33-35 to refer to a cognitive disorder, to Alzheimer’s disease, and to schizophrenia. Support for these claims may be found throughout the application and for instance at page 2 lines 1-17 and page 13 lines 4-36 of the application as filed. Also, Applicant respectfully directs the Examiner to information provided in an Appendix attached herein, providing evidence supporting the usefulness of the present compounds in the treatment of cognitive disorders through experimental data including dosage regimens.


With regard to claim 15, Applicant respectfully directs the Examiner to paragraph 258 of the application as published by the US Patent and Trademark Office. This paragraph states that the dose of an active compound can vary depending on factors such as the route of administration, age and weight of a patient, nature and severity of the disease and similar factors; and that any reference to an effective amount of formula I refers to these factors. Applicant respectfully notes that the amount indicated in claim 15 as filed is expressly directed to administration to a patient in need. In view of the uncertainty of an effective amount needed from one patient to the next, Applicant respectfully requests that the Examiner reconsider this rejection.

In the event that any one of claims 15, 33, 34 or 35 overcomes the present rejection, Applicant will be pleased to consider canceling some other claims of this group at the Examiner’s request to facilitate allowance of the application.

At pages 6-10 of the present Action, the Examiner rejects claims 1-4 and 26 as not reasonably providing enablement for solvates or prodrugs of specified compounds. In response, Applicant respectfully submits that the terms “solvates” and “prodrugs” no longer occur in claims 1-4 and 26, and requests that the Examiner withdraw this rejection therefore. The deletion of these terms is intended without prejudice.

At least in view of the foregoing comments, Applicant respectfully requests that all pending rejections be considered as overcome, and requests consideration for allowance. In the event that the Examiner believes any further issues may be resolved by telephone, the Examiner is invited to contact the below-signed representative firm to discuss.

Respectfully submitted,


Valerie Neymeyer-Tynkov (Reg. No. 46956)
Attorney for Applicants

Date: July 26, 2010
IpHorgan Ltd.
1130 Lake Cook Road, Suite 240
Buffalo Grove, IL 60089
Tel: 847-808-5500
Fax: 847-808-7238

Email: mail@iphorgan.net